公开(公告)号：AT483458T

公开(公告)日：2010-10-15

申请号：AT07291392

申请日：2007-11-23

Applicant: SERVIER LAB

Inventor： SPEDDING MICHAEL ,  MOCAER ELISABETH

IPC: A61K31/165 ,  A61P25/00

Abstract: A living animal body including a human, afflicted with periventricular leukomalacia comprises administering to the living animal body, an amount of agomelatine or N-[2-(7-methoxy-1-naphthyl)ethyl]acetamide, or its hydrate, crystalline form, or addition salt with acid or base that is effective for treatment of periventricular leukomalacia. The agomelatine is in crystalline form II. ACTIVITY : Cerebroprotective; Vasotropic. MECHANISM OF ACTION : Melatoninergic system receptor agonist; 5-HT-2C receptor antagonist.

公开(公告)号：PT1842535E

公开(公告)日：2010-09-28

申请号：PT07290420

申请日：2007-04-06

Applicant: SERVIER LAB

Inventor： MILLAN MARK ,  MOCAER ELISABETH ,  DELALLEAU BRUNO ,  FABIANO AGNES

IPC: A61K31/165 ,  A61P25/22

公开(公告)号：ME02767B

公开(公告)日：2010-06-30

申请号：MEP50408

申请日：2006-09-08

Applicant: SERVIER LAB

Inventor： MOCAER ELISABETH

IPC: A61K31/165 ,  A61K31/5375 ,  A61P25/24

公开(公告)号：BRPI0704453A2

公开(公告)日：2009-09-08

申请号：BRPI0704453

申请日：2007-11-23

Applicant: SERVIER LAB

Inventor： MOCAER ELISABETH ,  FABIANO AGNES

IPC: A61K31/165 ,  A61P25/00 ,  A61P43/00

Abstract: Use of agomelatine (I) or its hydrates, crystalline forms and acid or base addition salts, to obtain a drug to treat Smith Magenis syndrome, is claimed. An independent claim is included for a composition comprising (I) optionally in combination with excipients. ACTIVITY : Antidepressant; Hypnotic; Cardiovascular-Gen.; Anorectic. MECHANISM OF ACTION : 5-Hydroxytryptamine-2C antagonist; Melatoninergic receptor agonist.

公开(公告)号：GEP20094746B

公开(公告)日：2009-07-27

申请号：GEAP2007010391

申请日：2007-11-22

Applicant: SERVIER LAB

Inventor： MOCAER ELISABETH ,  FABIANO AGNES

IPC: A61K31/165 ,  A61P25/00 ,  A61P43/00

Abstract: This invention refers to the use of agomelatine, N-[2-(7-methoxy-1-naphthyl)ethyl] acetamide for production of preparation aimed at treating Smith-Magenis syndrome.

公开(公告)号：ES2313590T3

公开(公告)日：2009-03-01

申请号：ES06291421

申请日：2006-09-08

Applicant: SERVIER LAB

Inventor： MOCAER ELISABETH

IPC: A61K31/5375 ,  A61K31/165 ,  A61P25/24

Abstract: Asociación de agomelatina, o N-[2-(7-metoxi-1-naftil)etil]acetamida, o de uno de sus hidratos, formas cristalinas y sales de adición de un ácido o de una base farmacéuticamente aceptable, y un agente inhibidor de la recaptura de la noradrenalina o que permite aumentar la concentración de noradrenalina a nivel extracelular.

公开(公告)号：HK1118216A1

公开(公告)日：2009-02-06

申请号：HK08109494

申请日：2008-08-26

Applicant: SERVIER LAB

Inventor： SPEDDING MICHAEL ,  MOCAER ELISABETH

IPC: A61K20060101 ,  A61P20060101

Abstract: A living animal body including a human, afflicted with periventricular leukomalacia comprises administering to the living animal body, an amount of agomelatine or N-[2-(7-methoxy-1-naphthyl)ethyl]acetamide, or its hydrate, crystalline form, or addition salt with acid or base that is effective for treatment of periventricular leukomalacia. The agomelatine is in crystalline form II. ACTIVITY : Cerebroprotective; Vasotropic. MECHANISM OF ACTION : Melatoninergic system receptor agonist; 5-HT-2C receptor antagonist.

公开(公告)号：DK1769798T3

公开(公告)日：2008-11-24

申请号：DK06291421

申请日：2006-09-08

Applicant: SERVIER LAB

Inventor： MOCAER ELISABETH

IPC: A61K31/5375 ,  A61K31/165 ,  A61P25/24

Abstract: Association (I) of agomelatine (N-[2-(7-methoxy-1-naphthyl) ethyl]acetamide) and an agent inhibiting noradrenalin recapture or permitting the increase of noradrenalin concentration at the extracellular level. ACTIVITY : Antidepressant; Neuroleptic; Tranquilizer; Hypnotic. MECHANISM OF ACTION : Melatoninergic receptor system agonist; 5-Hydroxytryptamine receptor antagonist.

公开(公告)号：BRPI0704179A

公开(公告)日：2008-07-08

申请号：BRPI0704179

申请日：2007-11-23

Applicant: SERVIER LAB

Inventor： SPEDDING MICHAEL ,  MOCAER ELISABETH

IPC: A61K31/165 ,  A61P25/00

Abstract: A living animal body including a human, afflicted with periventricular leukomalacia comprises administering to the living animal body, an amount of agomelatine or N-[2-(7-methoxy-1-naphthyl)ethyl]acetamide, or its hydrate, crystalline form, or addition salt with acid or base that is effective for treatment of periventricular leukomalacia. The agomelatine is in crystalline form II. ACTIVITY : Cerebroprotective; Vasotropic. MECHANISM OF ACTION : Melatoninergic system receptor agonist; 5-HT-2C receptor antagonist.

公开(公告)号：AU2007234600A1

公开(公告)日：2008-06-12

申请号：AU2007234600

申请日：2007-11-22

Applicant: SERVIER LAB

Inventor： MOCAER ELISABETH ,  SPEDDING MICHAEL

IPC: A61K31/165 ,  A61P25/00

Abstract: A living animal body including a human, afflicted with periventricular leukomalacia comprises administering to the living animal body, an amount of agomelatine or N-[2-(7-methoxy-1-naphthyl)ethyl]acetamide, or its hydrate, crystalline form, or addition salt with acid or base that is effective for treatment of periventricular leukomalacia. The agomelatine is in crystalline form II. ACTIVITY : Cerebroprotective; Vasotropic. MECHANISM OF ACTION : Melatoninergic system receptor agonist; 5-HT-2C receptor antagonist.